Home Analyst Ratings Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%. The OCGN stock volume traded 95.97 million shares. In the past week, OCGN stock shed -2.68%. In the past three and six months, the OCGN stock gained 288.26% and 3864.39% respectively.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

How Ocugen’s Covaxin is giving competition to Pfizer and Moderna

On 22nd April 2021, announced that Bharat Biotech that is the co-development partner had made progress in a late-stage investigation of COVAXIN. COVAXIN is an vaccine being developed for COVID-19


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The investigation of COVAXIN was in its stage III and the second interval examination exhibited a positive consequence of 78% viability for COVID-19 in mild, moderate serious COVID-19 indications and variations while the investigation likewise guarantees that in the extreme instances of COVID-19, COVAXIN showed 100% response. The examination likewise had a subgroup of members for RT-PCR test and tracked down that the viability against asymptomatic COVID-19 disease was 70%.

How effective is Covaxin?

Ocugen has stated recently that Covaxin neutralizes the Brazil Variant, the U.K. Variation, and the double mutant in India variant in a research study. Researchers at the Indian Council of Medical Research performed in vitro tests utilizing sera from Covaxin-inoculated people. This is plainly significant information – particularly thinking about that new strains have made progress all throughout the planet.

Read More

India is at present immunizing with Covaxin; Bharat said it’s given the vaccine to a few million individuals there. The nation conceded the immunization crisis approval prior in the year – even before Bharat procured stage 3 outcomes. The most recent stage 3 information show the antibody is 78% effective after the subsequent dose.

Pfizer and Moderna are effective against the UK and South African strains and are further investigating booster shots to increase immunity and be broadly administered against new variants. While Moderna is waiting on data for the Indian double mutant variant, Pfizer’s partner BioNTech claims that they are confident Pfizer vaccine can handle the Indian variant.

Can Ocugen Inc. knock out its competitors in the big league?

While the Ocugen shares have rallied higher year to date as compared to performance of Pfizer and Moderna, we need to first grasp how COVID vaccines work. One type of vaccines uses the mRNA technology which triggers the body to make a viral protein against which the immunity is built while the second and more traditional form of vaccine is using the dead or weakened cells of the virus to stimulate immune response.

mRNA vaccines used by Pfizer and Moderna can be boosted again and again to enhance the immunity against new variants and strains however the traditional method used by Covaxin is a slower process. This can give Ocugen’s competitors an edge in the long term if COVID-19 virus becomes more and more complicated due to emergence of new variants- making mRNA based vaccine more adaptable and coming on top.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

About Ocugen Inc.

Ocugen Inc. is a biopharmaceutical company that is focused on the designing, developing, and commercializing of innovative therapies that aim to target the unmet needs of patients with diseases.  The transformative therapies that the company designs are gene therapies that specifically developed for targeting blindness diseases and restoration of sight. Ocugen Inc. uses proprietary modifier gene therapy platform which has become a breakthrough in treating multiple retinal diseases with one drug. Furthermore, OCGN stock has novel therapies for the treatment of age-related macular degeneration (AMD), diabetic reinopathy and diabetic macular edema.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Energous Corporation Inc. (WATT) stock declines during after-market. Here’s to know why?

Energous Corporation Inc. (WATT) stock gained by 7.05% at last close whereas the WATT stock price plunged by 7.82% in the after-hours trading session....

AMAZON Inc. (AMZN) stock fell during after-market. Here’s the update

Amazon Inc. (NASDAQ: AMZN) stock plunged by 0.84% at last close however moving ahead the AMZAN share price also declines by 7.44% in the...

Cocrystal Pharma Inc. (COCP) stock soars during current market. Here’s what you should know

Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused...

Why did Corvus Pharmaceuticals Inc. (CRVS) stock soar on Wednesday?

Corvus Pharmaceuticals Inc. (CRVS) shares surged 9.17% in after-hours on Wednesday, July 28, 2021, and closed the daily trading at $2.38. in the regular...

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

ImmunoPrecise Inc. (IPA) stock fell during pre-market. What’s the update?

ImmunoPrecise Inc. (NASDAQ: IPA) stock declined by 8.39% at last close while the IPA stock-price plunge by 4.87% in pre-market as well. ImmunoPrecise is...

ECMOHO Ltd. (MOHO) stock plunged during pre-market. Let’s see what’s happening?

ECMOHO Ltd. (NASDAQ: MOHO) stock gained by 7.05% at last close, while during pre-market MOHO stock has been seen declining by 7.75%. In China's...

Synthetic Biologics Inc. (SYN) stock plunged during pre-market. Here’s what you should know?

Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading....

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam